Multicenter Open-label, Long-term Safety Trial of Treatment Extension With ZD1839 in Patients Who Have Been Treated in Other ZD1839 Clinical Trials

Trial Profile

Multicenter Open-label, Long-term Safety Trial of Treatment Extension With ZD1839 in Patients Who Have Been Treated in Other ZD1839 Clinical Trials

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Breast cancer; Lung cancer
  • Focus Adverse reactions; Registrational
  • Sponsors AstraZeneca
  • Most Recent Events

    • 03 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 12 Feb 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as per ClinicalTrial.gov record..
    • 12 Feb 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2015 as per ClinicalTrial.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top